150 related articles for article (PubMed ID: 34270186)
1. Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?
Chengappa M; Desai A; Go R; Poonacha T
Oncology (Williston Park); 2021 Jul; 35(7):390-396. PubMed ID: 34270186
[TBL] [Abstract][Full Text] [Related]
2. Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines.
Poonacha TK; Go RS
J Clin Oncol; 2011 Jan; 29(2):186-91. PubMed ID: 21149653
[TBL] [Abstract][Full Text] [Related]
3. Category of evidence and consensus underlying National Comprehensive Cancer Network guidelines: Is there evidence of progress?
Desai AP; Go RS; Poonacha TK
Int J Cancer; 2021 Jan; 148(2):429-436. PubMed ID: 32674225
[TBL] [Abstract][Full Text] [Related]
4. Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines.
Noy MA; Rich BJ; Llorente R; Kwon D; Abramowitz M; Mahal B; Mellon EA; Zaorsky NG; Dal Pra A
Adv Radiat Oncol; 2022; 7(1):100832. PubMed ID: 34869943
[TBL] [Abstract][Full Text] [Related]
5. Evolution in the Presence and Evidence Category of Radiation Therapy Treatment Recommendations in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.
Conger RL; Mora J; Straza MW; Erickson BA; Lawton CAF; Schultz CJ; Currey A; Bedi M; Siker ML; Hall WA
Adv Radiat Oncol; 2023; 8(4):101206. PubMed ID: 37152489
[TBL] [Abstract][Full Text] [Related]
6. Roundtable discussion: Incorporating bone marrow transplantation into NCCN guidelines.
Vaughan WP; Silver SM; Beatty PG; Tallman MS
Oncology (Williston Park); 1998 Nov; 12(11A):390-2. PubMed ID: 10028522
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019.
Desai AP; Chengappa M; Go RS; Poonacha TK
Cancer; 2020 Aug; 126(16):3742-3749. PubMed ID: 32497271
[TBL] [Abstract][Full Text] [Related]
9. The management of hematologic malignancies during the COVID-19 pandemic.
Hus I; Salomon-Perzyński A; Tomasiewicz K; Robak T
Expert Opin Pharmacother; 2021 Apr; 22(5):565-582. PubMed ID: 33342308
[No Abstract] [Full Text] [Related]
10. Evidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines.
Liu X; Tang LL; Mao YP; Liu Q; Sun Y; Chen L; Lin JC; Ma J
Oncologist; 2019 Apr; 24(4):498-504. PubMed ID: 30459237
[TBL] [Abstract][Full Text] [Related]
11. Quality and methods of developing practice guidelines.
Cruse H; Winiarek M; Marshburn J; Clark O; Djulbegovic B
BMC Health Serv Res; 2002; 2():1. PubMed ID: 11825346
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for Palliative and Hospice Care in NCCN Guidelines for Treatment of Cancer.
Mo L; Urbauer DL; Bruera E; Hui D
Oncologist; 2021 Jan; 26(1):77-83. PubMed ID: 32915490
[TBL] [Abstract][Full Text] [Related]
13. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting.
Lishner M; Avivi I; Apperley JF; Dierickx D; Evens AM; Fumagalli M; Nulman I; Oduncu FS; Peccatori FA; Robinson S; Van Calsteren K; Vandenbroucke T; Van den Heuvel F; Amant F
J Clin Oncol; 2016 Feb; 34(5):501-8. PubMed ID: 26628463
[TBL] [Abstract][Full Text] [Related]
14. International adaptations of NCCN Clinical Practice Guidelines in Oncology.
Carlson RW; Larsen JK; McClure J; Fitzgerald CL; Venook AP; Benson AB; Anderson BO
J Natl Compr Canc Netw; 2014 May; 12(5):643-8. PubMed ID: 24812133
[TBL] [Abstract][Full Text] [Related]
15. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
Boyiadzis M; Bishop MR; Abonour R; Anderson KC; Ansell SM; Avigan D; Barbarotta L; Barrett AJ; Van Besien K; Bergsagel PL; Borrello I; Brody J; Brufsky J; Cairo M; Chari A; Cohen A; Cortes J; Forman SJ; Friedberg JW; Fuchs EJ; Gore SD; Jagannath S; Kahl BS; Kline J; Kochenderfer JN; Kwak LW; Levy R; de Lima M; Litzow MR; Mahindra A; Miller J; Munshi NC; Orlowski RZ; Pagel JM; Porter DL; Russell SJ; Schwartz K; Shipp MA; Siegel D; Stone RM; Tallman MS; Timmerman JM; Van Rhee F; Waller EK; Welsh A; Werner M; Wiernik PH; Dhodapkar MV
J Immunother Cancer; 2016; 4():90. PubMed ID: 28018601
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for supportive care and best supportive care in NCCN clinical practice guidelines for treatment of cancer: Differences between solid tumor and hematologic malignancy guidelines.
Mo L; Urbauer DL; Bruera E; Hui D
Support Care Cancer; 2021 Dec; 29(12):7385-7392. PubMed ID: 34052931
[TBL] [Abstract][Full Text] [Related]
17. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-6. Burkitt lymphoma (BL).
Ishizawa K
Int J Hematol; 2019 Sep; 110(3):265-271. PubMed ID: 31297687
[No Abstract] [Full Text] [Related]
18. Evaluating the quality of clinical guidelines. Linking decisions to medical evidence.
Djulbegovic B; Hadley T
Oncology (Williston Park); 1998 Nov; 12(11A):310-4. PubMed ID: 10028514
[TBL] [Abstract][Full Text] [Related]
19. The NCCN Guidelines Development Program.
Winn RJ; Botnick W; Dozier N
Oncology (Williston Park); 1996 Nov; 10(11 Suppl):23-8. PubMed ID: 8953592
[TBL] [Abstract][Full Text] [Related]
20. Hematologic Malignancies Discovered on Investigation of Breast Abnormalities.
Alsadi A; Lin D; Alnajar H; Brickman A; Martyn C; Gattuso P
South Med J; 2017 Oct; 110(10):614-620. PubMed ID: 28973700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
